Trials / Terminated
TerminatedNCT05744128
CD8 Minibody Repeatability Study
Positron Emission Tomography Repeatability Evaluation of Tissue Zirconium 89Zr Crefmirlimab Berdoxam
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- ImaginAb, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Zr-89 crefmirlimab berdoxam is a Zirconium-89 labelled minibody developed by ImaginAb for full body PET imaging of CD8+ cell distribution (CD8 ImmunoPET). The primary objective of this study is to assess the test-retest repeatability of CD8 immunoPET imaging in oncology patients with stable disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Zirconium 89Zr crefmirlimab berdoxam | Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution. |
Timeline
- Start date
- 2023-02-16
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
- First posted
- 2023-02-24
- Last updated
- 2024-12-03
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05744128. Inclusion in this directory is not an endorsement.